Stock Analiz

AMGN vs MRNA stock comparison

Amgen vs. Moderna · data as of November 13, 2026

Amgen (AMGN) has a market value of about $251.9B, Moderna (MRNA) about $90.4B. Over their latest twelve months Amgen had revenue of $38.9B and Moderna $2.5B.

On our five checks Amgen scores higher: 2.4 out of 5 (weak) against 1.0 (weak).

By area, the stronger company is Amgen on future growth; Amgen on track record; Amgen on shareholder returns.

Amgen leads on 14 of the compared lines and Moderna on 2.

Side by side

AMGNMRNA
Size and price
Market cap$251.9B$90.4B
Share price$465.67$223.37
Score
Overall score (of 5)2.41.0
Value00
Future growth31
Track record31
Financial health22
Shareholder returns41
Valuation
P/E (TTM)27.0—
Forward P/E19.5—
Price / free cash flow26.3—
Price / sales6.535.8
EV / EBITDA17.1—
PEG9.18—
DCF value vs. price−26%—
Business
Revenue$38.9B$2.5B
Net income$9.4B-$2.8B
Free cash flow$9.6B-$2.0B
Net margin24.1%-110.5%
Gross margin (5-yr avg.)69.9%59.9%
ROIC (5-yr avg.)13.5%9.4%
Growth
Revenue growth (1 yr)10.0%-39.9%
Revenue growth (5 yrs, per year)7.6%19.3%
EPS growth (5 yrs, per year)2.9%—
Balance sheet and payouts
Net cash (cash minus debt)-$40.8B$3.9B
Dividend yield2.16%None
Shareholder yield2.2%0.0%
Analysts
Upside to average target−7%−29%
Consensus ratingHoldHold

Highlighted = the better figure on that line. Revenue, net income and free cash flow: AMGN TTM to September 30, 2026, MRNA TTM to September 30, 2026. Not investment advice.

Frequently asked questions

Which is the better stock, Amgen or Moderna?

We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Amgen scores 2.4 out of 5 and Moderna 1.0; the table shows where each one is stronger.

Which grows faster, Amgen or Moderna?

Over five years Moderna grew revenue about 19.3% a year and Amgen about 7.6% a year.

Which pays a higher dividend?

Amgen yields 2.16% and Moderna nothing (no dividend).

Full Amgen analysis → Full Moderna analysis →

More comparisons

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.